Romosozumab
Based on 1 publication(s) in Google Scholar
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.
For research use only. We do not sell to patients.
- Purity: 99.11%
- CAS No.: 909395-70-6
- Molecular Weight:146.32 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Romosozumab
More
Biological Activity
Human IgG2 kappa
Human
SOST/Sclerostin
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male cynomolgus monkeys[1]
-
Dosage:30 mg/kg
-
Administration:Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
-
Result:Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 kappa
ELISA, FACS, Functional assay
-
Immobilized SOST Protein, Human can bind Romosozumab. The EC50 for this effect is 12.46 ng/mL.
Chemical Information
-
CAS No. 909395-70-6
-
Appearance Liquid
-
Molecular Weight 146.32 kDa
-
Color Colorless to light yellow
-
SMILES
[Romosozumab]
-
Synonyms
AMG-785; CDP-7851
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Phytomedicine
Schisandrol B inhibits osteoclastogenesis and mitigates estrogen deficiency-induced bone loss by targeting TRAF6-NOX1 pathway. [Abstract]2025 Dec 5:150:157669. PMID: 41435606
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855. [Content Brief]
[2]. Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz